Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

High loading dose of clopidogrel may overcome effects of CYP2C19 genetic variant in persons with CAD

Sep. 23, 2010

Fixed-dose fenofibrate/pravastatin plus ezetimibe reduces hyperlipidemia in type 2 diabetes

Sep. 23, 2010

First selective Aurora kinase A inhibitors identified

Sep. 23, 2010

Peretinoin shows potential as first-line agent to prevent recurrence of HCC

Sep. 22, 2010

Phase III data presented on bisoprolol vs. carvedilol in elderly subjects with CHF

Sep. 22, 2010

Galapagos develops new phosphodiesterase 1A inhibitors for osteoarthritis

Sep. 22, 2010

Palau Pharma identifies new histamine H4 receptor antagonists

Sep. 22, 2010

Preliminary phase I data on fully human anti-PNAG mAb F-598 disclosed

Sep. 22, 2010

SCH-527123 is safe and efficacious in phase II trial in COPD

Sep. 21, 2010

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Sep. 21, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...